René L. Roux

A Real-World Retrospective Observational Study of Patients with Advanced/Recurrent Endometrial Cancer Across England

Jamie Wallis, Shammi Luhar, Filipa Tunaru, Lewis Carpenter et autres

cz, gb, it (code pays fourni par la source)

Ceralasertib (cerala) + olaparib (ola) in patients (pts) with homologous recombination repair (HRR)-deficient platinum-sensitive relapsed ovarian cancer (OC) after progression on prior PARP inhibitor (PARPi) treatment (tx).

René L. Roux, Sophie Postel‐Vinay, Mario Campone, Antoîne Italiano et autres

gb, fr, us, kr (code pays fourni par la source)

Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer

Rebecca Kristeleit, Michael-John Devlin, Andrew R. Clamp, Charlie Gourley et autres

gb (code pays fourni par la source)

Efficacy and safety of neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab in patients with HER2-positive early breast cancer - A retrospective study

Leila Koudsi, C. Hockaday, N C Levitt, Mark Tuthill et autres

The surgical, histopathological characteristics, and survival outcome of ovarian clear cell carcinoma: a retrospective case series sharing the experience of a tertiary cancer centre

Sally S. El‐Tawab, Sabina Nistor, René L. Roux, Sanjiv Manek et autres

gb, Égypte (code pays fourni par la source)

196 Has the introduction of poly(ADP-Ribose) polymerase inhibitors changed the advanced ovarian cancer treatment pathway? A bird’s-eye view of the English advanced ovarian cancer treatment landscape

Jamie Wallis, Federica Picariello, Lewis Carpenter, Zsófia Kiss et autres

de, it, gb (code pays fourni par la source)

407 COPELIA: a 3-arm randomised phase II trial of weekly paclitaxel with or without cediranib or olaparib with cediranib in recurrent endometrial cancer

Andrew R. Clamp, Catharine Porter, Ann White, Alys Irving et autres

gb (code pays fourni par la source)

110 PROMPT: phase II trial of maintenance pembrolizumab following weekly paclitaxel for recurrent ovarian, fallopian tube or peritoneal cancer

Tami Grunewald, Rowan Miller, Laura A. Tookman, Iain A. McNeish et autres

gb (code pays fourni par la source)

Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer

Shibani Nicum, Naomi McGregor, Rachel Austin, Linda Collins et autres

gb (code pays fourni par la source)

821TiP Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis)

Geoffrey I. Shapiro, Bristi Basu, Anthony B. El-Khoueiry, Sophie Postel‐Vinay et autres

us, gb, fr, kr (code pays fourni par la source)

The clinicopathological characteristics and survival outcomes of primary expansile vs. infiltrative mucinous ovarian adenocarcinoma: a retrospective study sharing the experience of a tertiary centre

Sabina Nistor, Sally S. El‐Tawab, Flora Y. Wong, Andreas Zouridis et autres

gb, Égypte, cn (code pays fourni par la source)

A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)

Thomas Starkey, Maria C. Ionescu, Michaël Tilby, Martin Little et autres

gb (code pays fourni par la source)